We developed single cell-derived clonal expansion following MPC derivation from SCNT-hPSCs to offer a pure population and a higher biological activity. Additionally, we investigated the therapeutic effects of SCNT-hPSC-MPCs in model mice of Asherman's syndrome (AS), which is characterized by synechiae or fibrosis with endometrial injury.
| INTRODUC TI ON
It is now accepted that human pluripotent stem cells (hPSCs), such as embryonic stem cells (ESCs) and reprogrammed stem cells from somatic cells using Yamanaka factors or somatic cell nuclear transfer (SCNT), will be available as cell sources in regenerative medicine. [1] [2] [3] [4] [5] Recently, we successfully established SCNT-derived human PSCs (SCNT-hPSCs) using patient fibroblasts 4, 6 and have constantly decondensation, required novel tools, such as SCNT-hPSCs, to study their mechanism or develop clinical treatments. Because oocytes produce many proteins involved in the modulation of chromatin decondensation and mitochondria, SCNT-hPSCs may provide some clues to overcome the demerits in the concept of therapeutic cloning.
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Additionally, SCNT-hPSCs with a low risk of immune rejection is now the subject of interest, likely to be further applied in clinical trials.
In this study, we developed single cell-derived clonal expansion following MPC derivation from SCNT-hPSCs to offer a pure population and a higher biological activity. Additionally, we investigated the therapeutic effects of SCNT-hPSC-MPCs in Asherman's syndrome (AS), which is characterized by synechiae or fibrosis with endometrial injury, often leading to infertility. A proliferation of endometrial cells should be proceeded to treat AS. However, treatment is difficult due to the intricate machinery of basal layer production or loss of stem cells in the endometrium. 16, 17 In this regard, MPCs could be a possible candidate to treat fibrosis of AS because they contain paracrine properties that encompass both angiogenic and anti-inflammatory effects. In the present study, we addressed, for the first time, that single cell-derived clonally expanded SCNT-hPSC-MPCs (SCNThPSC-MPC-SCDs) showed increased cell numbers with stable population doublings (PDs) and no teratomas. These cells contributed to F I G U R E 1 Schematic diagram describing the protocol for differentiation of somatic nuclear transfer-derived human pluripotent stem cells into mesenchymal progenitor cells (SCNT-hPSC-MPCs). The formation of embryonic bodies (EBs) from PSCs was performed using SB431542, and then, EBs were reseeded in culture dishes for 28 d; the resultant cells are referred to as MPCs. Using MPCs detached in single-cell suspension, single cell-derived MPCs were clonally expanded in culture plates for at least 23 d. To examine the functions of the generated SCNT-hPSC-MPCs, their in vitro cellular activity was evaluated in confluent MPCs, and cells were applied to the Asherman's syndrome (AS) in vivo model. After cell transplantation in the uterus of the AS model, the assessment of the therapeutic effects was carried out at day 7 reduction in fibrosis in the AS model, resulting in implantation via promoted angiogenesis. Moreover, these cells show functional resemblance to hESC-MPCs. Thus, the successful generation of functional SCNT-hPSC-MPCs can promote therapeutic advances using the novel alternative in regenerative medicine.
| MATERIAL S AND ME THODS

| Culture of human PSCs and differentiation into MPCs
All experiments were performed under authorization from the and were maintained as described previously. The characteristics of SCNT-PSCs (CHA-hNT5) were provided in Figure S2 . As an experimental control, bone marrow (BM)-MPCs (PT2501, Lonza, Walkersville, MD) were used. During the differentiation of MPCs, the medium was changed every 3 days. For details, a schematic illustration of the differentiation protocol is provided in Figure 1 .
| Cell proliferation assay
For the analysis of cell growth during long-term culture, cells were maintained in expansion culture as follows: 5 × 10 4 cells per well were plated in 12-well culture dishes, and the cells were counted in triplicate at least until 75 days after plating. The PDs and doubling time between cell passages were evaluated as previously described. 18 The single cell-derived MPCs were expanded and/or then combined to analyse their doubling time. 
| Induction of a mouse model of AS
| Statistical analysis
All results are presented as the mean ± SE. Statistical analyses were performed using the Mann-Whitney U test for comparisons between two groups and the Kruskal-Wallis ANOVA test for >2 groups.
Values of P < 0.05 were considered to denote statistical significance.
GraphPad Prism ver. 4 software (GraphPad Software, La Jolla, CA, USA) was used for statistical analysis.
| RE SULTS
| Effective differentiation and validation of MPCs from human PSCs
The generated CHA-hES15 and CHA-hNT5 cells from our laboratory were used in the present study ( Figure S1 ). 4, 20 Because the TGF-beta inhibitor SB431542 is a known inducer that can reproduce mesodermal lineage cells, 21 it was mainly used to encourage the commitment of the mesodermal lineage during EB formation. To effectively acquire the MPC population, two phased protocols were explored: and SSEA4 were hardly detected in both hPSC-MPC-SCDs, while SSEA4 was expressed in hBM-MPCs at 46.0%, similar to that reported previously ( Figure 3D ). 26 In the case of pluripotency genes, the expression levels of OCT4, SOX2 and NANOG were highly reduced during differentiation ( Figure 3E ). The precursor genes for multilineage differentiated cells, precursor markers for each lineage, C/EBPα, RUNX2 and SOX9, were clearly expressed in both hPSC-MPC-SCDs. Maturation-related genes PPARγ for adipocytes, COL1 for osteocytes and COMP for chondrocytes were detected following differentiation ( Figure 3F ). Next, we performed confirmative differentiation for lineage cells from SCNT-hPSC-MPC-SCDs, and we found strong adipogenesis, osteogenesis and chondrogenesis in both hPSC-MPC-SCDs ( Figure 3G ).
In our first data, we found that cell proliferation and PDs of the SCNT-hPSC-MPC-SCD were remarkably discriminated from BMMPCs ( Figure 3H and Figure S3 ). Furthermore, we investigated whether the capacity for clonal propagation and differentiation of hPSC-MSC-SCDs can synergistically increase when MPCs obtained from single cells were combined. To address this, we newly adopted -fold; in CHA-hNT5-MPCs, 10 14 -fold). In the present study, we have found that hPSC-MPC-SCD did not show more proliferative capacity than hPSC-MPC. However, although most hPSC-MPC-SCDs can undergo limited passaging up to approximately 14 passages, their proliferating capacity is unarguably outstanding, suggesting the great value in the concept of therapeutic cell numbers.
Next, to examine whether these proliferative hPSC-MPCs were safe from teratomas, we carried out the teratoma formation test. hPSC-MPCs were injected into the testis of immunocompromised mice and were observed for 3 months. As shown
in Figure 3I , all hPSC-MPC-SCDs did not produce teratomas ( Figure 3I ). However, teratomas or teratomas with cysts were clearly formed in parent CHA-hES15 and CHA-hNT5 cells. Based on the present data, we found that our safe and productive protocol for MPC differentiation from SCNT-hPSCs can generate clinically applicable MPCs.
| Establishment of a murine model of AS and inhibition of pro-inflammatory factors in mice treated with SCNT-MPC-SCD
We next sought to elucidate whether transplanted SCNT-hPSC-MPC-SCDs can function as highly efficient therapeutic sources
F I G U R E 3 Generation of stable single cell-derived clonally expanded SCNT-hPSC-MPCs (SCNT-hPSC-MPC-SCDs). (A) Schematic diagram of single cell-derived clonally expanded MPCs for the treatment of Asherman's syndrome (AS). (B)
The morphology of MPCs derived from both hPSC-MPCs is similar to that of adult tissue-derived MPCs. After 5 passages, cells had a normal karyotype, implying no senescence. Bars, 100 μm. Magnification, ×20. (C) No difference between hESC-and SCNT-hPSC-MPCs was detected in the efficiency of seeding and doubling. When single MPCs were manually seeded into one well of a 96-well plate, the survival rate excluded from seeding damage and capacity for proliferation of survived single MPCs were very similar, suggesting the resemblance of SCNT-hPSC to hESCs. (D) FACS analysis showed that the markers for MPCs, CD29, CD44 and CD105 were highly increased in both hPSC-MPC-SCDs but not in stem cell or hematopoietic markers, suggesting phenotypical maturation. (E) Genes displaying stemness were rarely detected and were gradually decreased upon differentiation. (F) In multiple lineage differentiation, the PPARγ, C/EBPα for adipocytes, COL1, RUNX2 for osteocytes and COMP, SOX9 for chondrocytes in hPSC-MPCs were detected by differentiation. All transcripts were expressed in multilineage cell differentiation. (G) To confirm their maturation, hPSC-MPCs using standard differentiation conditions for adipogenesis, osteogenesis and chondrogenesis were differentiated; however, adipogenesis was not fully differentiated in MPC status, suggesting the not full maturation of hPSC-MPCs into adipocyte, osteocyte and chondrocyte. (H) The cellular activities of both hPSC-MPC-SCDs displayed that proliferation by day and passage and high population doublings were increased. PDs and cumulative cell number were presented in terms of single cell preparation at passage 5. The data are presented as the means ± SE from at least three experiments. Asterisks depict statistically significant differences compared with adult BM-MPCs (**P < 0.05). (I) No teratomas in both SCNT-hPSC-MPC-SCDs were observed, implying safety in the clinic applications under pathologic condition. Similar with protocol by Alawadhi et al, 19 we established the AS mouse model and prepared stem cells were directly injected into uterus after incision in anaesthetized mice. No remarkable difference in H&E staining was detected among the wild-type, hBM-MPC-treated, both hPSC-MPCtreated groups, suggesting morphologic recovery into normal endometrium. However, the uteri of AS displayed a low frequency of small-sized glandular epithelium in the stroma and a low density of cells in the stroma, implying fibrosis (Figure 4Ai ). In trichrome staining, a blue-coloured region presenting fibrosis was also displayed in the AS uterus. However, the MPC-treated groups seemed to be recovered, shown as a reddish colour in the stroma, implying The data are presented as the means ± SE from at least three experiments. Asterisks depict statistically significant differences compared with the AS model (**P < 0.05, *P < 0.01). (C) Consistent with the levels of proteins, the PCR data showed that proinflammatory factors were highly increased in the AS model, but were significantly decreased by MSC therapy. The data are presented as the means ± SE from at least three experiments. Asterisks depict statistically significant differences compared with the AS model. Two independent experiments were performed (**P < 0.05, *P < 0.01).
cellular fidelity (Figure 4Aii) . Additionally, aberrant expression of COL1A1 was detected in the AS uterus (Figure 4Aiii ) likely due to abundant collagen fibres and cell proliferative arrest, similar no previous pathogenic events. 27 Additionally, single-layered luminal epithelial cells, which are arrested by AS induction and are located on surface of endometrium, were highly increased by stem cell therapy (Figure 4Aiv ). The proliferation of luminal epithelial cells was shown by an enlarged panel with nuclei ( Figure 4Av ). Fibrosis is closely involved with the failure of embryo implantation due to a defective endometrium. 28 To investigate whether transplanted F I G U R E 5 Impaired implantation in the AS uterus can be ameliorated in the hPSC-MPC-SCD-treated group by angiogenesis of host cells.
(A) Assessment of implantation failure using the AS model. (B) The average number of pups is shown. Statistical analysis of (A), presented as the means ± SE from at least three experiments. Asterisks depict statistically significant differences compared with implantation from the AS model. Graphs from 2 independent experiments are shown. N = 6 per group. (all group except AS = 6 horns, AS = 24 horns). (**P < 0.05, *P < 0.01). (C) Host murine cells upregulate the angiogenic factors, including Hgf, Igf, Ang-1 and Vegf-a. To determine whether the high cytokine levels were derived from human or murine cells, real-time PCR was performed using human-and mouse-specific primers. Most cytokines were murine, not human, and were highly sustained at day 14. Individual values were normalized to rPL7. The data for B and C are presented as the means ± SE from at least three experiments. Asterisks depict statistically significant differences compared with implantation from the AS model (**P < 0.05, *P < 0.01). (D) The capillary density was measured by counting Ki-67 + (green) and CD31 + cells (blue). DAPI was used to detect nuclei (red colours). Statistical analyses of the panels and values are presented as the mean ± SE from at least randomly selected 15 fields from four mouse heads per group. Two independent experiments were performed. N = 6 per group. (all group except AS = 6 horns, AS = 24 horns). (**P < 0.05, *P < 0.01) Magnification, ×40.
SCNT-hPSC-MPC-SCDs contributed to fibrosis by the suppression of pro-inflammatory factors in the uterus, Western blotting was carried out using pro-inflammatory-related factors TGFß1 and COL1A1. As shown in Figure However, signals for X-and Y-chromosome probes in the AS-induced mouse uterus were not detected at day 7 after transplantation of MPCs, and it may suggest that transplanted human cells could be disappeared ( Figure S4 ). The suboptimal number of IS in the uterus with AS could be caused by insufficient angiogenesis because blood vessels play a role to deliver nutrients and growth litters. Moreover, it is well known that MPCs function to increase angiogenesis through paracrineangiogenic factors. 29, 30 To prove this, we determined the capillary density in both hPSC-MPC-SCD-treated groups in the AS condition where the formation of new blood vessels is needed to prevent fibrosis. 31 Intriguingly, we found that angiogenic factors were highly increased in the uterus receiving MPCs, even 7 days after therapy. for endothelium) and Ki67 (a cell proliferation marker). As shown in Figure 5D , proliferation of endothelial cells was similar between CHA-hES15-MPCs and CHA-hNT5-MPCs but was not observed in the AS group (in sham: 12.9 ± 7.1%; in AS: 0 ± 0%; in hBM-MPCs:
| Regeneration of damaged uteri in AS by SCNT-MPC-SCD transplantation via enhanced angiogenesis from host cells
57.0 ± 6.5%; in CHA-hES15-MPC-SCDs: 77.7 ± 14.9%; in CHA-hNT5-MPC-SCDs: 67.5 ± 7.5%) ( Figure 5D ). These data directly indicate that SCNT-hPSC-MPCs dramatically increased the angiogenic effects in the AS uterus, resulting in improved uterine function for pregnancy.
| D ISCUSS I ON
In the present study, we first established single cell-derived clonally expanded MPCs from human pluripotent stem cells using somatic cell nuclear transfer technology. The salient findings for MPCs. In addition, production of these novel cells suggests that therapy using SCNT-hPSC-MPCs can be an innovative modality for specific patients with an incurable disease in regenerative medicine. 
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